Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ADRO Trial: ADX-629 in Atopic Dermatitis
NCT05717920Phase 2Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Feb 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acloproxalap in atopic dermatitis (AD) (3 arms), sponsored by Aldeyra Therapeutics. Primary endpoint: Adverse Event Query. Started Feb 2023; status: completed.
02
Drugs
acloproxalap
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05717920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717920.